Q2 2026 13F · SEC CIK 1224962

Perceptive Advisors LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $6.4B
Reported positions: 101
Top holdings a year, 3 yrs: +30.2%
Assets under management: $11.8B

Perceptive Advisors LLC is a hedge fund that reported 101 positions worth $6.4B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Praxis Precision Medicines I (PRAX, 10.6%), Spyre Therapeutics (SYRE, 6.0%), Celcuity Inc (CELC, 5.2%). A portfolio copying its top holdings returned 30.2% a year over the last 3 years, against 22.3% for the S&P 500.

Perceptive Advisors LLC holdings largest 50 of 101 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Perceptive Advisors LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
PRAXPraxis Precision Medicines I	10.6%	13.0%	2,035,986	+0.0%	$681.6M
SYRESpyre Therapeutics	6.0%	3.8%	4,319,496	+14.2%	$383.5M
CELCCelcuity Inc	5.2%	7.1%	3,197,200	+2.2%	$334.5M
ASNDAscendis Pharma A/s	4.8%	—	1,163,721	—	$310.4M
RYTMRhythm Pharmaceuticals Inc	4.5%	4.1%	2,586,295	+9.0%	$287.2M
ROIVRoivant Sciences Ltd	4.5%	4.5%	8,085,461	-2.4%	$286.1M
RLAYRelay Therapeutics Inc	4.1%	1.9%	14,106,187	+44.7%	$263.9M
TVTXTravere Therapeutics Inc	3.3%	2.4%	3,752,574	-9.4%	$213.2M
KARDKardigan Inc	3.0%	—	8,200,662	—	$195.6M
NUVLNuvalent Inc	3.0%	3.2%	1,580,505	+0.0%	$195.2M
EWTXEdgewise Therapeutics Inc	2.8%	2.8%	4,373,974	-1.1%	$177.7M
APGEApogee Therapeutics Inc	2.7%	2.6%	1,308,113	-15.1%	$173.6M
AMLXAmylyx Pharmaceuticals Inc	2.3%	2.3%	8,334,882	+0.6%	$149.7M
MGTXMeiragtx Hldgs PLC	2.3%	1.8%	10,786,658	+4.5%	$145.7M
ORKAOruka Therapeutics Inc	2.0%	1.4%	1,345,063	-3.6%	$128.0M
INBXInhibrx Biosciences Inc	1.9%	1.9%	1,297,763	-10.0%	$123.0M
PTGXProtagonist Therapeutics Inc	1.9%	2.6%	981,879	-20.2%	$120.4M
SLDBSolid Bioscience Inc.	1.9%	1.7%	11,906,646	+0.0%	$118.9M
ZYMEZymeworks Inc	1.7%	1.7%	4,182,953	+19.2%	$109.3M
TNGXTango Therapeutics Inc	1.6%	—	3,377,000	—	$105.6M
IMTXImmatics NV	1.6%	2.0%	10,383,456	+0.0%	$105.2M
NRIXNurix Therapeutics Inc	1.6%	1.1%	4,320,422	+16.4%	$104.8M
BCRXBiocryst Pharmaceuticals Inc	1.6%	1.4%	10,308,888	+38.7%	$103.1M
RVMDRevolution Medicines Inc	1.5%	0.5%	527,600	+104.0%	$98.8M
AVLNAvalyn Pharmaceuticals Inc	1.4%	—	2,675,296	—	$88.1M
DYNDyne Therapeutics Inc	0.9%	1.7%	2,689,235	-42.4%	$59.7M
BIIBBiogen Inc	0.9%	—	276,173	—	$59.7M
IMVTImmunovant Inc	0.8%	0.8%	1,357,383	-15.0%	$52.3M
UNHUnitedhealth Group Inc	0.8%	—	116,806	—	$48.5M
IONSIonis Pharmaceuticals Inc	0.7%	0.8%	566,000	+12.3%	$44.9M
STROSutro Biopharma Inc	0.7%	—	1,304,846	—	$43.3M
ANROAlto Neuroscience Inc	0.7%	0.9%	1,609,893	-19.9%	$42.5M
JAZZJazz Pharmaceuticals PLC	0.6%	0.6%	170,000	+0.0%	$41.0M
CRVSCorvus Pharmaceuticals Inc Com	0.6%	0.7%	2,667,441	+16.4%	$39.9M
829401108Sionna Therapeutics Inc	0.6%	0.5%	905,000	+37.4%	$39.8M
CTMXCytomx Therapeutics Inc.	0.6%	0.9%	10,439,185	+3.4%	$39.1M
AORTArtivion Inc	0.6%	1.2%	1,737,290	+6.1%	$39.0M
XFORX4 Pharmaceuticals Inc	0.6%	0.6%	7,933,491	+17.7%	$37.0M
CORTCorcept Therapeutics Inc	0.5%	—	398,385	—	$34.6M
RGENRepligen Corp	0.5%	0.7%	248,212	-11.5%	$33.9M
AVRAnteris Technologies Global	0.5%	—	3,425,476	—	$33.7M
RAPPRapport Therapeutics Inc	0.5%	—	773,342	—	$32.2M
GLTODamora Therapeutics Inc	0.5%	0.6%	1,223,000	+0.0%	$31.8M
CRLCharles Riv Labs Intl Inc	0.5%	—	140,000	—	$31.8M
AXSMAxsome Therapeutics, Inc.	0.5%	0.5%	118,450	-21.0%	$29.0M
DBVTDbv Technologies S A	0.4%	—	1,653,350	—	$27.1M
IRTCIrhythm Technologies Inc	0.4%	—	223,766	—	$26.6M
ADPTAdaptive Biotechnologies Corp	0.4%	—	1,217,325	—	$26.1M
SABSSab Biotherapeutics Inc	0.4%	0.5%	6,627,501	+3.0%	$25.8M
DHRDanaher Corp Del	0.4%	—	130,000	—	$24.8M

What Perceptive Advisors LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +17.4% /yr; S&P 500 +11.7%
3 years: +30.2% /yr; S&P 500 +22.3%
5 years: +0.7% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$6.4B	101
Q1 2026	$5.0B	91
Q4 2025	$5.4B	111
Q3 2025	$3.4B	90
Q2 2025	$2.7B	82
Q1 2025	$2.8B	86
Q4 2024	$3.6B	97
Q3 2024	$4.7B	102
Q2 2024	$4.1B	107
Q1 2024	$5.7B	105
Q4 2023	$4.5B	97
Q3 2023	$3.0B	87

Questions about Perceptive Advisors LLC's portfolio

What stocks does Perceptive Advisors LLC own?

Perceptive Advisors LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 101 positions worth $6.4B. The largest are Praxis Precision Medicines I (PRAX) at 10.6%, Spyre Therapeutics (SYRE) at 6.0%, Celcuity Inc (CELC) at 5.2%, Ascendis Pharma A/s (ASND) at 4.8% and Rhythm Pharmaceuticals Inc (RYTM) at 4.5%.

What did Perceptive Advisors LLC buy last quarter?

In Q2 2026, Perceptive Advisors LLC added Revolution Medicines Inc (RVMD) (+104.0% shares), Relay Therapeutics Inc (RLAY) (+44.7% shares) and Biocryst Pharmaceuticals Inc (BCRX) (+38.7% shares), compared with its Q1 2026 filing.

What did Perceptive Advisors LLC sell last quarter?

In Q2 2026, Perceptive Advisors LLC cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Nautilus Biotechnology Inc (NAUT), cut from its top 50 enGene Holdings Inc. (ENGN), cut from its top 50 Intuitive Surgical Inc (ISRG), Dyne Therapeutics Inc (DYN) (-42.4% shares), Axsome Therapeutics, Inc. (AXSM) (-21.0% shares) and Protagonist Therapeutics Inc (PTGX) (-20.2% shares), compared with its Q1 2026 filing.

How has Perceptive Advisors LLC's portfolio performed?

A portfolio copying Perceptive Advisors LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +30.2% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +17.4% against +11.7%. Over 5 years: +0.7% a year against +10.6%.

When is Perceptive Advisors LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Perceptive Advisors LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Perceptive Advisors LLC manage?

Perceptive Advisors LLC reported $11.8B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $6.4B.